FOURTH AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT BETWEEN THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH AND ATARA BIOTHERAPEUTICS, INC.Research and Development Collaboration Agreement • February 28th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Fourth Amended and Restated Research and Development Collaboration Agreement (“Fourth Restated Agreement”), entered into on December 17, 2021 (“Execution Date”), and effective as of the Execution Date, is made by and between Atara Biotherapeutics, Inc., having its principal offices at 611 Gateway Blvd #900, South San Francisco, CA 94080, (“Atara”), and the Council of the Queensland Institute of Medical Research, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”). Each of Atara and Institute are referred to in this Agreement as a “Party”, and collectively as the “Parties”
RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT BETWEEN ARPEGGIO BIOSCIENCES AND INTRINSIC MEDICINEResearch and Development Collaboration Agreement • April 8th, 2022 • Intrinsic Medicine, Inc. • Biological products, (no disgnostic substances) • Colorado
THIS RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT (the “Agreement”) made and entered into as of Dec 22, 2020 (the “Effective Date”), by and between ARPEGGIO BIOSCIENCES, INC. (“Arpeggio”) at [***] and INTRINSIC MEDICINE, INC. (“Intrinsic”) at [***], Arpeggio and Intrinsic are hereinafter referred to individually as a “Party” and jointly as “Parties.”
RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT between NEXTCURE, INC. and ELI LILLY AND COMPANYResearch and Development Collaboration Agreement • April 12th, 2019 • NextCure, Inc. • Pharmaceutical preparations • New York
This RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT (this “Agreement”) is effective as of November 2, 2018 (the “Effective Date”), and is entered into by and between:
RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENTResearch and Development Collaboration Agreement • March 21st, 2022 • NAAC Holdco, Inc. • Communications services, nec
Now, therefore, in consideration of the foregoing and of the mutual covenants and agreements contained herein, the receipt and sufficiency of which is hereby acknowledged, and subject to the Condition Precedent, the Parties agree as follows:
AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT between THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH and ATARA BIOTHERAPEUTICS, INC,Research and Development Collaboration Agreement • August 1st, 2018 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Research and Development Collaboration Agreement (“Agreement”), entered into on 23 September, 2016 (“Execution Date”), and effective as of the Original Effective Date (as defined below), is made by and between Atara Biotherapeutics, Inc., having its principal offices at 611 Gateway Blvd #900, South San Francisco, CA 94080, (“Atara”), and the Council of the Queensland Institute of Medical Research, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”). Each of Atara and Institute are referred to in this Agreement as a “Party”, and collectively as the “Parties”
RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT between NEXTCURE, INC. and ELI LILLY AND COMPANYResearch and Development Collaboration Agreement • January 30th, 2019 • NextCure, Inc. • Pharmaceutical preparations • New York
This RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT (this “Agreement”) is effective as of November 2, 2018 (the “Effective Date”), and is entered into by and between:
RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENTResearch and Development Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development CollaborationResearch and Development Collaboration Agreement • January 13th, 2020
Current methods used to diagnose AD remain invasive and relatively complex. Therefore, there is a need to develop and establish reliable, less invasive and efficient biomarkers and technologies in clinical practice. To address this, Nordic Bioscience has been pioneering the development of blood-based biomarkers for decades and is therefore the ideal partner for identifying molecular fingerprints in blood of patients. This supports Vivoryon’s therapeutic approach of targeting neurotoxic pGlu-Abeta by inhibiting its producing enzyme Glutaminyl Cyclase.
Avacta and Mologic Enter Research and Product Development Collaboration Agreement · Avacta's Affimer technology will be used to develop rapid lateral flow diagnostics for clinical applications · Development and commercialisation partnership in point...Research and Development Collaboration Agreement • December 29th, 2018
Wetherby and Cambridge, UK, 13 June 2016: Avacta Group plc (AIM: AVCT) ("Avacta" or "the Group") the developer of Affimer® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today announced they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care (POC) testing, using Avacta's Affimer technology. As stated at the time of Avacta's interim results, establishing commercial relationships in the POC testing market is one of the Company's key strategic objectives.
DATED 2014Research and Development Collaboration Agreement • August 18th, 2015
[or] [[Insert name of university], [a corporation incorporated by Royal Charter (insert number),]1 whose administrative offices are at [• ]
EXHIBIT 10.10A CONFIDENTIAL TREATMENT REQUESTED (*) Denotes information for which confidential treatment has been requested. Confidential portions omitted have been filed separately with the Commission. AMENDMENT TO NEUREX/WARNER RESEARCH AND...Research and Development Collaboration Agreement • March 31st, 1997 • Neurex Corp/De • Biological products, (no disgnostic substances)
SECOND AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT BETWEEN THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH AND ATARA BIOTHERAPEUTICS, INC.Research and Development Collaboration Agreement • November 7th, 2019 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Second Amended and Restated Research and Development Collaboration Agreement (“Second Restated Agreement”), entered into on 28th August 2019 (“Execution Date”), and effective as of the Execution Date, is made by and between Atara Biotherapeutics, Inc., having its principal offices at 611 Gateway Blvd #900, South San Francisco, CA 94080, (“Atara”), and the Council of the Queensland Institute of Medical Research, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”). Each of Atara and Institute are referred to in this Agreement as a “Party”, and collectively as the “Parties”
